|
Acute intermittent porphyria
|
0.020 |
Biomarker
|
disease |
BEFREE |
Seven out of 10 clones were amylase alpha-2A, the autoantibody to which was specifically detected in sera from patients with AIP and fulminant type 1 diabetes (FT1DM) [T. Endo, S. Takizawa, S. Tanaka, M. Takahashi, H. Fujii, T. Kamisawa, T. Kobayashi, Amylase alpha-2A autoantibodies: novel marker of autoimmune pancreatitis and fulminant type 1 diabetes mellitus, Diabetes 58 (2009) 732-737].
|
19520060 |
2009 |
|
Acute intermittent porphyria
|
0.020 |
Biomarker
|
disease |
BEFREE |
These results suggest that an autoantibody against amylase alpha-2A is a novel diagnostic marker for both AIP and fulminant type 1 diabetes and that, clinically and immunologically, AIP and fulminant type 1 diabetes are closely related.
|
19001184 |
2009 |
|
Acute interstitial pneumonia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Seven out of 10 clones were amylase alpha-2A, the autoantibody to which was specifically detected in sera from patients with AIP and fulminant type 1 diabetes (FT1DM) [T. Endo, S. Takizawa, S. Tanaka, M. Takahashi, H. Fujii, T. Kamisawa, T. Kobayashi, Amylase alpha-2A autoantibodies: novel marker of autoimmune pancreatitis and fulminant type 1 diabetes mellitus, Diabetes 58 (2009) 732-737].
|
19520060 |
2009 |
|
Acute interstitial pneumonia
|
0.020 |
Biomarker
|
disease |
BEFREE |
These results suggest that an autoantibody against amylase alpha-2A is a novel diagnostic marker for both AIP and fulminant type 1 diabetes and that, clinically and immunologically, AIP and fulminant type 1 diabetes are closely related.
|
19001184 |
2009 |
|
Autoimmune pancreatitis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Seven out of 10 clones were amylase alpha-2A, the autoantibody to which was specifically detected in sera from patients with AIP and fulminant type 1 diabetes (FT1DM) [T. Endo, S. Takizawa, S. Tanaka, M. Takahashi, H. Fujii, T. Kamisawa, T. Kobayashi, Amylase alpha-2A autoantibodies: novel marker of autoimmune pancreatitis and fulminant type 1 diabetes mellitus, Diabetes 58 (2009) 732-737].
|
19520060 |
2009 |
|
Autoimmune pancreatitis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Amylase alpha-2A autoantibodies: novel marker of autoimmune pancreatitis and fulminant type 1 diabetes.
|
19001184 |
2009 |
|
Autosomal dominant retinitis pigmentosa
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A statistically significant lod score of 3.9 is obtained for the RP locus and AMY2 at a recombination frequency of 1%.
|
879170 |
1977 |
|
Carcinoid Tumor
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Nucleotide sequence analysis showed that the amylase expressed in this carcinoid tumor has 13 and 6 amino acid substitutions when compared with salivary amylase (Amy1) and pancreatic amylase (Amy2), respectively.
|
2701942 |
1989 |
|
Carcinoid tumor no ICD-O subtype
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Nucleotide sequence analysis showed that the amylase expressed in this carcinoid tumor has 13 and 6 amino acid substitutions when compared with salivary amylase (Amy1) and pancreatic amylase (Amy2), respectively.
|
2701942 |
1989 |
|
Diabetes
|
0.010 |
Biomarker
|
disease |
BEFREE |
Seven out of 10 clones were amylase alpha-2A, the autoantibody to which was specifically detected in sera from patients with AIP and fulminant type 1 diabetes (FT1DM) [T. Endo, S. Takizawa, S. Tanaka, M. Takahashi, H. Fujii, T. Kamisawa, T. Kobayashi, Amylase alpha-2A autoantibodies: novel marker of autoimmune pancreatitis and fulminant type 1 diabetes mellitus, Diabetes 58 (2009) 732-737].
|
19520060 |
2009 |
|
Diabetes Mellitus
|
0.010 |
Biomarker
|
group |
BEFREE |
Seven out of 10 clones were amylase alpha-2A, the autoantibody to which was specifically detected in sera from patients with AIP and fulminant type 1 diabetes (FT1DM) [T. Endo, S. Takizawa, S. Tanaka, M. Takahashi, H. Fujii, T. Kamisawa, T. Kobayashi, Amylase alpha-2A autoantibodies: novel marker of autoimmune pancreatitis and fulminant type 1 diabetes mellitus, Diabetes 58 (2009) 732-737].
|
19520060 |
2009 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.020 |
Biomarker
|
disease |
BEFREE |
Seven out of 10 clones were amylase alpha-2A, the autoantibody to which was specifically detected in sera from patients with AIP and fulminant type 1 diabetes (FT1DM) [T. Endo, S. Takizawa, S. Tanaka, M. Takahashi, H. Fujii, T. Kamisawa, T. Kobayashi, Amylase alpha-2A autoantibodies: novel marker of autoimmune pancreatitis and fulminant type 1 diabetes mellitus, Diabetes 58 (2009) 732-737].
|
19520060 |
2009 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.020 |
Biomarker
|
disease |
BEFREE |
These results suggest that an autoantibody against amylase alpha-2A is a novel diagnostic marker for both AIP and fulminant type 1 diabetes and that, clinically and immunologically, AIP and fulminant type 1 diabetes are closely related.
|
19001184 |
2009 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.040 |
Biomarker
|
disease |
BEFREE |
We found potent pancreatic α-amylase inhibition in Astilbe thunbergii root extract (AT) and confirmed that AT treatment in a T2DM rat model reduces post-starch administration blood glucose levels.
|
28743229 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.040 |
Biomarker
|
disease |
BEFREE |
The acylated flavonol glycoside montbretin A (MbA) and its precursor myricetin 3-<i>O</i>-(6'-<i>O</i>-caffeoyl)-glucosyl rhamnoside (mini-MbA) are potent inhibitors of human pancreatic α-amylase and are being developed as drug candidates to treat type-2 diabetes.
|
29967287 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
These animals are also a source of pancreatic α-amylase inhibitors, which have the ability to control the glucose level in the blood and can be used for the treatment of prediabetes and type 2 diabetes mellitus.
|
31546678 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.040 |
Biomarker
|
disease |
BEFREE |
Structures of human pancreatic α-amylase in complex with acarviostatins: Implications for drug design against type II diabetes.
|
21111049 |
2011 |
|
Fulminant type 1 diabetes mellitus
|
0.010 |
Biomarker
|
disease |
BEFREE |
Seven out of 10 clones were amylase alpha-2A, the autoantibody to which was specifically detected in sera from patients with AIP and fulminant type 1 diabetes (FT1DM) [T. Endo, S. Takizawa, S. Tanaka, M. Takahashi, H. Fujii, T. Kamisawa, T. Kobayashi, Amylase alpha-2A autoantibodies: novel marker of autoimmune pancreatitis and fulminant type 1 diabetes mellitus, Diabetes 58 (2009) 732-737].
|
19520060 |
2009 |
|
Hyperamylasemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Coexpression of the AMY1 gene and AMY2 gene (pancreatic type) was observed in most of the lung cancers without hyperamylasemia, lung tissue, and cells scraped from the tracheal epithelium, thyroid, and female genital tract (ovary, fallopian tube, and uterus cervix), while minimal levels of mRNA transcripts of the AMY2 gene were detected in other malignant neoplasms, various normal tissues, and the cultured cell lines.
|
7507116 |
1994 |
|
Hyperglycemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Astilbe thunbergii reduces postprandial hyperglycemia in a type 2 diabetes rat model via pancreatic alpha-amylase inhibition by highly condensed procyanidins.
|
28743229 |
2017 |
|
Hyperglycemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
In this study, the inhibitory effects of loquat leaf extract (LLE) on pancreatic α-amylase and α-glucosidase, and the preventative effects of LLE on hyperlipidemia and hyperglycemia in rats induced by a high fat and fructose diet have been evaluated.
|
28124052 |
2017 |
|
Hyperglycemia
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Intestinal and pancreatic α-amylase and α-glucosidase inhibitors offer an approach to lower the levels of post-prandial hyperglycemia through the control of dietary starch breakdown in digestion.
|
28170007 |
2017 |
|
Hyperlipidemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, the inhibitory effects of loquat leaf extract (LLE) on pancreatic α-amylase and α-glucosidase, and the preventative effects of LLE on hyperlipidemia and hyperglycemia in rats induced by a high fat and fructose diet have been evaluated.
|
28124052 |
2017 |
|
Lafora Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
We report studies on the efficacy and CNS delivery of VAL-0417, an antibody-enzyme fusion composed of the 3E10 hFab and human pancreatic α-amylase, in a mouse model of LD.
|
31329461 |
2019 |
|
Malignant neoplasm of lung
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Coexpression of the AMY1 gene and AMY2 gene (pancreatic type) was observed in most of the lung cancers without hyperamylasemia, lung tissue, and cells scraped from the tracheal epithelium, thyroid, and female genital tract (ovary, fallopian tube, and uterus cervix), while minimal levels of mRNA transcripts of the AMY2 gene were detected in other malignant neoplasms, various normal tissues, and the cultured cell lines.
|
7507116 |
1994 |